New York State Common Retirement Fund Purchases 14,398 Shares of Repligen Co. (NASDAQ:RGEN)

New York State Common Retirement Fund lifted its position in shares of Repligen Co. (NASDAQ:RGEN) by 2.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 581,442 shares of the biotechnology company’s stock after buying an additional 14,398 shares during the quarter. New York State Common Retirement Fund’s holdings in Repligen were worth $83,693,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Ballentine Partners LLC grew its position in shares of Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after buying an additional 72 shares in the last quarter. CIBC Asset Management Inc lifted its stake in shares of Repligen by 5.0% during the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 81 shares during the last quarter. MML Investors Services LLC lifted its stake in shares of Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock worth $503,000 after purchasing an additional 89 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Repligen by 15.2% during the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 90 shares during the last quarter. Finally, Louisiana State Employees Retirement System lifted its stake in shares of Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock worth $2,087,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Up 3.8 %

Shares of RGEN stock opened at $150.73 on Thursday. The stock’s 50-day simple moving average is $155.04 and its 200-day simple moving average is $148.71. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a market capitalization of $8.45 billion, a PE ratio of -407.37, a P/E/G ratio of 4.12 and a beta of 0.99. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $207.87.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. TD Cowen started coverage on Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 price objective for the company. Wolfe Research started coverage on Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. HC Wainwright decreased their price target on Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Finally, Canaccord Genuity Group started coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $182.91.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.